DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $252,924 | -48.1% | 12,260 | -25.8% | 0.00% | -100.0% |
| Q2 2023 | $487,535 | +29.3% | 16,521 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $377,119 | +6.8% | 16,368 | +28.9% | 0.00% | 0.0% |
| Q4 2022 | $353,215 | -28.2% | 12,701 | -20.7% | 0.00% | 0.0% |
| Q3 2022 | $492,000 | +61.3% | 16,018 | +54.6% | 0.00% | 0.0% |
| Q2 2022 | $305,000 | -7.0% | 10,358 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $328,000 | -34.1% | 10,518 | -7.3% | 0.00% | 0.0% |
| Q4 2021 | $498,000 | -15.3% | 11,352 | -3.7% | 0.00% | 0.0% |
| Q3 2021 | $588,000 | -12.9% | 11,785 | +36.9% | 0.00% | 0.0% |
| Q2 2021 | $675,000 | -52.9% | 8,611 | -56.4% | 0.00% | -75.0% |
| Q1 2021 | $1,433,000 | -4.3% | 19,730 | +10.4% | 0.00% | 0.0% |
| Q4 2020 | $1,497,000 | +127.5% | 17,866 | -2.7% | 0.00% | +100.0% |
| Q3 2020 | $658,000 | – | 18,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |